Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-37
RECRUITING9
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO17%
Delay Index: of 6 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SSGJ-707 NCT06493760 |
P2 | Recruiting | Metastatic Colorectal Cancer | 130 | 2025-06 |
| 608 NCT06222671 |
P2 | Recruiting | Axial Spondyloarthritis | 180 | 2025-09-22 |
| 611 NCT06639295 |
P3 | Active, not recruiting | Sinusitis; Nasal Polyps | 243 | 2025-12 |
| 611 NCT07042126 |
P3 | Recruiting | Dermatitis, Atopic | 180 | 2026-06-30 |
| 608 dose NCT07261644 |
P3 | Recruiting | Ankylosing Spondylitis | 500 | 2027-01-14 |
| 610 NCT06680947 |
P2 | Active, not recruiting | Asthma | 225 | 2027-02 (+5 mo) |
| 610 NCT06323213 |
P3 | Recruiting | Asthma | 480 | 2027-02 (+8 mo) |
| SSGJ-613 100 mg Q12W NCT07708181 |
P2 | Not yet recruiting | Gout Arthritis | 200 | 2027-08-11 |
| 611 NCT07767253 |
P3 | Recruiting | Dermatitis, Atopic | 246 | 2027-09 |
| 608 NCT07349329 |
P3 | Not yet recruiting | Axial Spondyloarthritis, Non-Radiographic | 380 | 2028-04-19 |
| 626 NCT07185269 |
P1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 198 | 2028-08-12 |
| 611 NCT07039669 |
P3 | Recruiting | Pulmonary Disease, Chronic Obstructive (COPD) | 594 | 2028-09 |
| NCT07900867 NCT07900867 |
P2 | Not yet recruiting | Cutaneous Lupus Erythematosus (CLE) | 140 | 2028-12 |
| 627 NCT07507513 |
P2 | Recruiting | Ulcerative Colitis (UC) | 288 | 2029-02-28 |